Literature DB >> 9192370

A field trial of oil adjuvanten trivalent Actinobacillus pleuropneumoniae vaccine.

E Oishi1, T Kitajima, H Nakamura, C Matsuda, K Amimoto, H Yasuhara.   

Abstract

The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192370     DOI: 10.1292/jvms.59.421

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  1 in total

1.  Genome-wide screening of lipoproteins in Actinobacillus pleuropneumoniae identifies three antigens that confer protection against virulent challenge.

Authors:  Yurou Cao; Lulu Gao; Li Zhang; Lixiang Zhou; Jihong Yang; Lingfu Deng; Jin Zhao; Chao Qi; Jinlin Liu
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.